Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

BACKGROUND Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...

F. Pecci, Xinan Wang, Valentina Santo et al. · 0 citations
Review Open access Sep 2026

Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025.

Recent years have seen substantial advances in lung cancer management, with therapeutic options expanding rapidly through the integration of targeted therapies, immunotherapies, antibody-drug conjugates, and novel, immune-engaging agents. Although outcomes have improved for selected patients with non-small cell lung ca...

N. Florez, S. Patel, R. Salgia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.